Hydroxychloroquine Alleviates Cyclophosphamide-Induced Premature Ovarian Failure By Attenuating Granulosa Cell Senescence And Modulating The Mtdna-Cgas Pathway
Chemotherapy, while life-saving, can unfortunately lead to premature ovarian failure, a condition where the ovaries stop functioning normally before the age of 40. This often happens because chemotherapy drugs, like cyclophosphamide, cause important ovarian cells, called granulosa cells, to age prematurely. When these cells age and stop working correctly, it can lead to a decline in ovarian function, affecting fertility and hormone production.
Recent research has explored a potential way to mitigate this side effect using hydroxychloroquine, a medication commonly known for treating malaria and autoimmune diseases. The findings suggest that this drug can help protect the ovaries from chemotherapy-induced damage. It does this by slowing down the aging process of granulosa cells.
At a deeper level, the drug works by influencing a cellular pathway involving mitochondrial DNA (mtDNA) and a protein called cGAS. Essentially, chemotherapy can cause damage to the mitochondria (the powerhouses of our cells), leading to leakage of mtDNA. This leakage can trigger an inflammatory response through the cGAS pathway, which contributes to cell aging and damage. Hydroxychloroquine appears to stabilize mitochondrial function, reduce this mtDNA leakage, and dampen the inflammatory signals, thereby preserving the health and function of ovarian cells. This protective effect was observed to improve ovarian function, reduce the loss of egg-containing follicles, and normalize reproductive cycles in animal models, offering a promising avenue for preserving fertility in patients undergoing chemotherapy.
Source: link to paper